Protease Inhibitors in AIDS Therapy (Infectious Disease and Therapy). Questo articolo non è disponibile.Protease Inhibitors in AIDS Therapy (Infectious Disease and Therapy)

Details the evolution of HIV protease inhibitors from molecular development through medical applications!

Considering the latest class of revolutionary drugs fighting against HIV infection and AIDS, this comprehensive reference thoroughly examines the development and properties of HIV protease inhibitors from clinical and scientific perspectives, discussing how protease inhibitors changed the FDA approval process-enhancing the collaboration between regulatory authorities and drug developers.

Spotlights protease inhibitors as the cornerstone drugs of the first HAART regimens-key components of long-term viral suppression and immune restoration, and in secondary and tertiary regimens!

Evaluating protease inhibitors as therapeutic options and research tools, Protease Inhibitors in AIDS Therapy

reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS

highlights a variety of strategies and techniques for drug discovery and development illustrated by success stories of pharmaceutical companies and biotechnology start-up firms

summarizes the pharmacokinetics, metabolism, and drug interactions of protease inhibitors

details preliminary clinical studies on oral bioavailability, pharmacokinetic profiling, efficacy, resistance, and tolerability

describes available efficacy data for marketed inhibitors and those in clinical development

reports on efforts to manage antiviral resistance in the clinic and improve patient adherence to complex drug therapy

and more!
Containing more than 600 helpful literature references, drawings, photographs, and tables, Protease Inhibitors in AIDS Therapy serves for an essential reference for infectious disease specialists, epidemiologists, virologists, immunologists, pharmacologists, medicinal chemists and biochemists, microbiologists, hematologists, hepatologists, and medical students in these disciplines.

Foreword,
John G. Bartlett, The Johns Hopkins University School of Medicine, Baltimore, Maryland

HIV-1 Protease as a Target for AIDS Therapy,
John W. Erickson
Discovery and Early Development of Saquinavir,
Ian B. Duncan and Sally Redshaw
Discovery and Early Development of Ritonavir and ABT-378,
Dale J. Kemp
Discovery and Early Development of Indinavir,
Bruce D. Dorsey and Joseph P. Vacca
Discovery and Development of Nelfinavir (Viracept),
Siegfriend H. Reich
Design and Synthesis of Amprenavir, A Novel HIV Protease Inhibitor,
R. D. Tung, D. J. Livingston, B. G. Rao, E. E. Kim, C. T. Baker, J. S. Boger, S. P. Chambers, D. D. Delhinger, M. Dwyer, L. Elsayed, J. Fulghum, B. Li, M. A. Murcko, M. A. Navia, P. Novak, S. Pazhanisamy, C. Stuver, and J.A. Thomson
HIV Protease Inhibitors in Early Development,
R. Alan Chrusciel, Judith A. Nicholas, and Suvit Thaisrivongs
Pharmacology and Drug Interactions of HIV Protease Inhibitors,
Charles W. Flexner
Beneficial Pharmokinetic Interactions: Are Two Protease Inhibitors Better than One?,
Charles W. Flexner
Protease Inhibitors: Clinical Efficacy,
Roy M. Gulick
Toxicities and Adverse Effects of Protease Inhibitors,
Marshall J. Glesby
Resistance to HIV-1 Protease Inhibitors,
Benjamin Young and Daniel R. Kuritzkes
Expedited Drug Approval and HIV Protease Inhibitors,
Jeff Murray
Use of Protease Inhibitors in the Management of HIV/AIDS,
Richard C. Ogden and Charles W. Flexner